Causal claim
Sumitomo Pharma Antipsychotic TreatmentThe two move together: more cause, more effect. The map scores it at 33% confidence, weighed from 1 article.
Sumitomo Pharma's US subsidiary Sunovion won 2013 FDA approval for lurasidone (Latuda) in bipolar I depression, as monotherapy and adjunct to lithium or valproate.
None of these receipts match that. Try a looser word, or .
Nothing upstream on the map yet.